KaNDy Therapeutics Company
KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814. KaNDy Therapeutics develops a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and nighttime awakening. Launched in 2017, KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus.
Technology:
Cancer
Industry:
Longevity
Headquarters:
Stevenage, Herefordshire, United Kingdom
Founded Date:
2017
Employees Number:
1-10
Funding Status:
M&A
Investors Number:
5
Total Funding:
$32 589 510
Estimated Revenue:
$1M to $10M
Last Funding Date:
2018-08-29
Last Funding Type:
Series C
Register and Claim Ownership